Moderna's bivalent beta booster betters Spikevax versus omicron, pointing to promise of variant-specific jabs Regeneron sees skin cancer potential beyond PD-1s with $250M Checkmate acquisition Finch's nest thins out with 20% of employees cut in restructuring after FDA hold Sponsored: CDx Biomarkers for Oncology Research & Development Ouch! Acadia's non-opioid painkiller flunks midphase test, weakening a potential rival to Vertex Imara eliminates 83% of workforce—including chief medical officer—in wake of pipeline wipeout Sionna unveils with $111M series B to pursue quest for 'holy grail' cystic fibrosis target Axsome moves 'closer to judgement day' for stalled depression therapy New blood stem cell road map helps scientists learn from mistakes on quest to create cells in lab After rivals' FDA rebuffs, GSK targets class-first oral approval in chronic kidney disease anemia Another SPAC deal cracks as spine implant maker Accelus calls off Nasdaq plans Pharmas risk losing doctors to digital fatigue in the post-COVID-19 world if they don't get their email strategy right Study: Medicare Advantage saves seniors nearly $2K a year compared to fee-for-service Johnson & Johnson, after weak quarter of vaccine sales, will no longer include it in guidance Featured Story | By Nick Paul Taylor Moderna’s bivalent COVID-19 vaccine has bettered the antibody response of Spikevax against omicron when given as a booster, offering encouragement to the biotech as it races toward phase 2/3 data that will shape its offering for the next season of jabs. read more |
| |
|---|
|
Top Stories By James Waldron Regeneron has shown there is more to skin cancer drugs than PD-1 inhibitors through its $250 million acquisition of Checkmate Pharmaceuticals and its lead immuno-oncology asset vidutolimod. read more By Annalee Armstrong Finch Therapeutics’ nest is getting a bit smaller. Some 20% of the company's workforce is being let go amid a restructuring spurred by an FDA clinical hold and the pausing of a chronic hepatitis B program. read more Sponsored by: Precision for Medicine Biomarker discovery and development are critical for advancing oncology therapeutics and informing patient management. Experts discuss evaluating biomarkers in drug-diagnostic co-development programs. read more By Nick Paul Taylor Acadia Pharmaceuticals’ hopes of chasing Vertex into phase 3 have taken a big hit. Weeks after Vertex’s non-opioid painkiller chalked up a midphase win, Acadia’s rival candidate has failed in a similar setting, leaving its future in acute pain in doubt. read more By Gabrielle Masson After discontinuing development for its lead drug, Imara is cutting 83% of its workforce, a move that will leave the company with only six remaining full-time employees. read more By Max Bayer Sionna Therapeutics is jumping out of stealth mode with $111 million in series B funds to launch its cystic fibrosis portfolio. The company hopes to launch two assets into phase 1 trials within the next year. read more By Annalee Armstrong Axsome Therapeutics has agreed to a set of postmarketing conditions that the FDA proposed, which will help get its depression drug back on track after the agency identified deficiencies in the application last year. read more By Gabrielle Masson Researchers at UCLA have unveiled a novel road map tracking blood stem cell development in the human embryo, findings that could help develop new treatments for blood cancers and inherited blood disorders. read more By Fraiser Kansteiner Could the third time be the charm for an oral HIF-PH inhibitor in the U.S.? GlaxoSmithKline certainly hopes so, with its potential first-in-class medicine now officially up for a decision at the FDA by early next year. read more By Conor Hale After inking a $482 million deal to go public late last year, Accelus and its SPAC partner, CHP Merger Corp., have called it quits. read more By Ben Adams Healthcare professionals want high quality, low quantity and good structure when it comes to email campaigns. If they fail to get this balance right, pharma marketers risk entrenching so-called “digital fatigue” from doctors as the world comes out of the pandemic. read more By Robert King A new study from the Better Medicare Alliance found that Medicare Advantage beneficiaries saved nearly $2,000 on their total healthcare spending compared to those in fee-for-service Medicare. read more By Kevin Dunleavy After a disappointing quarter of sales for its COVID-19 vaccine, Johnson & Johnson will no longer include the vaccine in its revenue projections. J&J reported sales of the vaccine for the first quarter at $457 million, far off from Wall Street’s estimate of $785 million. The company also has reduced its overall revenue projection for the year. read more Resources Sponsored By: H1 More than 570 clinical trials in Ukraine have been disrupted. Unanticipated disruptions to medical testing and clinical trials impede progress toward new breakthroughs and new therapies that millions of patients around the world hang their hope on. What role do rescue sites play? Sponsored by: Nethealth Net Health, experts in wound care and dermatology clinical trials, have a new eBook: 5 Rules to Enhance Clinical Trials in 2022, find out how to recruit the right participants, connect patients and researchers with technology, manage costs and more. Sponsored by: United Cargo The United Cargo team has made a commitment to pharmaceutical and medical partners that we are equipped to support their vaccine transportation needs safely and effectively across our expansive global and domestic network. The safety and security of these commodities is our priority, and we are proud to be a trusted partner in these efforts. Download infographic now. Presented By: Springer Nature The journey of drug development in 2021 delivered to your inbox: top 10 AdisInsight drug profiles viewed, new drug profiles released, overview of drug launches, key deals, research trends in 2021 and much more (free of charge). Sponsored by: Blue Matter, strategic consultants in the life sciences What’s in store for the oncology market in 2022 and beyond? This paper looks at 5 trends driving the market. Sponsored by: Thermo Fisher Scientific Learn how to position quality as a central component within your raw material sourcing strategies for the chemicals used throughout your workflows. Download the free whitepaper from Thermo Fisher Scientific. Sponsored by: Oracle Health Sciences Learn about ways to break down regulatory roadblocks and get closer to 100% clarity on regulatory positions to advance decentralized clinical trials in research. Cancer Progress 2022: Hear from Leading Oncology Innovators May 10-12, 2022 | Virtual Accelerating Immuno-Oncology and Oncology Drug Development Using Humanized Mice Live & Recorded on: Thursday, April 21, 2022 | 12pm ET / 9am PT Fierce Trial Master File Summit May 2-4, 2022 | New Orleans, LA & Streaming Live Fierce Leaders in Life Sciences Forum May 24, 2022 | Free Virtual Event Fierce Digital Pharma Engage June 14-15, 2022 | Huntington Beach, CA Fierce Digital Pharma Innovation Week June 21-23, 2022 | Virtual Event Fierce Biotech Next Gen June 29-30, 2022 | Free Virtual Event Fierce Pharma PR & Communications Summit East July 19-20, 2022 | Jersey City, NJ Promotional Review Committee Compliance and Best Practices Summit West (PRC West) September 2022 | San Diego, CA Medical Affairs Strategic Summit West (MASS West) September 20-22, 2022 | San Diego, CA Fierce New Product Planning Summit September 20-22, 2022 | Boston, MA Fierce Digital Pharma East October 18-20, 2022 | Philadelphia, PA & October 25-28, 2022 | Virtual Event Fierce Pharma Marketing Awards October 19, 2022 | Philadelphia, PA Fierce Biotech Cell & Gene Therapy Forum October 19, 2022 | Virtual Event Fierce Pharma Meeting Professionals Summit November 2-3, 2022 | Atlantic City, NJ Fierce European Trial Master File Summit November 14-16, 2022 | London, UK Fierce Launch Readiness for Medical Affairs & Communications Teams Summit November 30-December 1, 2022 | Virtual Event Fierce JPM Week 2023 January 2023 | San Francisco, CA & Virtual | 